Lindsay Somerville is a Respiratory physician affiliated with University of Virginia. OpenAlex indexes 55 publications with 382 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- General Health, Attitudes, and Activity in Self-directed Exercise in Patients With Cystic Fibrosis (GAINS-CF)
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
77.9%Corticosteroid35%Trelegy Ellipta34%Symbicort20%Fluticasone Propionate16%Budesonide-Formoterol Fumarate13%Fluticasone Propionate Hfa9%Dulera8%Part D<11 patientsbeta2-Adrenergic Agonist20.5%Albuterol Sulfate Hfa78%Ventolin Hfa22%Part D<11 patients+ 3 more classes in this area
Anti-infectives
11.4%Macrolide Antimicrobial11.4%Azithromycin100%Part D≥22 patientsMetabolism & gastrointestinal
8.3%Corticosteroid5.8%Prednisone100%Part D≥15 patientsProton pump inhibitor2.5%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Importance of type 2 inflammation in cystic fibrosis patients with recurrent pulmonary exacerbations
University of Virginia
FY2026$192,840K23HL183757
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 416 Health-related social needs: impact on health care utilization in people with cystic fibrosis
Journal of Cystic Fibrosis
2025 - Evaluating Social Risk Factors and Their Influence on Lung Function, BMI, and Exacerbation Frequency in Patients With Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine
2025 - Epithelial expression of allergic inflammatory type 2 genes in adults with modulator-refractory cystic fibrosis
Annals of Allergy Asthma & Immunology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen Caldwell, MD
University of Virginia
Mark Deboer, MD
University of Virginia
Jaideep Kapur, MD
University of Virginia
Mark Quigg, MD, MSc
University of Virginia
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”